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Background: Aneuploidy is an important etiology of implantation failure and quantitative real-time polymerase chain
reaction (qPCR) seems a promising preimplantation genetic screening (PGS) technology to detect aneuploidies. This
verification study aimed at verifying the impact on reproductive outcomes in in vitro fertilization (IVF) cycles using fresh
embryo transfer (FET) in which the embryos were selected by blastocyst biopsy with qPCR-based PGS in our settings.
Results: A total of 13 infertile couples with more than once failed in vitro fertilization were enrolled during July to October
of 2014. PGS was conducted by qPCR with selectively amplified markers to detect common aneuploidies (chromosomes
13, 18, 21, X, and Y). The design of the qPCR molecular markers adopted the locked nucleic acid (LNA) strategy. The
blastocyst biopsy was performed on Day 5/6 and the PGS was done on the same day, which enabled FET. A total of 72
blastocysts were biopsied. Successful diagnoses were established in all embryos and the rate of successful diagnosis was
100 %. The aneuploidy rate was 38.9 % (28/72). 28 embryos were transferred. The clinical pregnancy rate was 61.5 % (8/13)
per cycle. Early first trimester abortion was encountered in 1 and the ongoing pregnancy rate was 53.8 % (7/13) per cycle.
Conclusion: This study verified the favorable outcome of adopting PGS with qPCR + FET in our own setting. Expanding
the repertoire of aneuploidies being investigated (from a limited set to all 24 chromosomes) is underway and a
randomized study by comparing qPCR and other PGS technologies is warranted.
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Preimplantation genetic screening (PGS) by Day 3 cleav-
age stage embryo biopsy followed by examination with
fluorescence in situ hybridization (FISH) was once popu-
lar strategy for women with advanced maternal age
(AMA) [1]. This strategy was based upon an assumption
that aneuploidy, which is associate with AMA, is an im-
portant factor for implantation failure and therefore* Correspondence: mchen_cch@yahoo.com
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[2]. However, a famous randomized study published by
Mastenbroek and colleagues reported that such FISH-
based PGS with Day 3 biopsy did not confer advantages
in women with AMA regarding the live-birth rates [3],
and it is then called the “Mastenbroek controversy”.
This unexpected finding was subsequently proved by
many randomized controlled trials [4] except in one
series [5]. Some other researchers thus proposed differ-
ent strategies including adopting different timing of bi-
opsy (trophectoderm biopsy versus cleavage-stage
blastomere biopsy), different molecular technologies
which can detect all 24 chromosomes instead of only a
few selected chromosomes (which is a major limitationcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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or frozen) [1, 6, 7].
Mounting evidences had suggested blastomere biopsy
at Day 3 cleavage stage embryos does impair the im-
plantation potential whereas trophectoderm biopsy at
Day 5/6 blastocyst does not [8–10]. Meanwhile, it is
straightforward that using more sophisticated molecular
tools may select a better or “more normal” embryo.
Competing technologies include array comparative gen-
omic hybridization (CGH), single nucleotide polymorph-
ism (SNP) array, quantitative real-time polymerase chain
reaction (qPCR), and next generation sequencing (NGS)
[11]. Amongst them, NGS remains to be mostly investi-
gational because of the resources and cost of bioinfor-
matics analyses [12, 13], and therefore the most feasible
tools at the present seem to be qPCR and array-based
technologies, including SNP array and array CGH
[8, 14–18]. It is now known that mosaicism is a common
phenomenon in early human embryo development, and
therefore how to select the embryos with best implan-
tation potential becomes a vital question [19]. It is shown
by the research groups who proposed for qPCR that qPCR
is superior to array CGH since it enjoys a lower false-
positive rate for aneuploidy detection (0 % for qPCR and
5.4 % for array CGH in 122 embryos analyzed), and
thereby preserving more embryos available for transfer
and ensues a better reproductive outcome [14].
There are now commercially available PGS platforms
using array CGH in the market (such as those produced
by BlueGnome, UK) and has become very popular be-
cause of the feasibility of an easy-to-use system, espe-
cially for in vitro fertilization (IVF) centers without a
genetic lab as a supporting resort [11]. However, since
the outcomes achieved by the team proposing qPCR are
compellingly excellent. It thus poses stress upon re-
searchers of the similar field to verify qPCR as a replace-
ment or an alternative to the current popular PGS by
array CGH platforms [14].
In this small verification study, we aimed to assess the
PGS by qPCR strategy coupled with trophectoderm bi-
opsy at Day 5/6 blastocyst stage. In the initial stage we
first verified qPCR only at selected common aneu-
ploidies including chromosome 13, 18, 21, X, and Y
(these aneuploidies can be confirmed by FISH). The rea-
sons we assessed only selected chromosomes are three:
First, the detail design and experimental conditions re-
garding qPCR on all 24 chromosomes are patent pro-
tected and we need staged efforts to devise and validate
our own. Therefore, in this study we adopted a method
called locked nucleic acid (LNA) technology to design
our qPCR platform [20]; Second, for a rapid overnight
diagnosis which is warranted for fresh embryo transfer
(FET), it takes a qPCR machine with a 384-well for only
one embryo [18], which may not be feasible in realsettings in most genetic labs; Third, we believe the
“Mastenbroek controversy” may result not only from
lacking an effective genotyping system to screen a “bet-
ter” embryo, but also from the proven impairment of the
implantation potential when biopsy at Day 3 cleavage
stage embryos [3, 4, 6]. The team proposing qPCR in
one hand arguing qPCR is better than FISH because it
can examine all 24 chromosomes but in the other hand
claiming despite array CGH should have a better reso-
lution than qPCR whereas implying array CGH is “too
sensitive” since it has a more false-positive rate when
SNP array is used as a gold standard [14, 16, 18]. We
thus are interested to know if it is feasible by using a
limited qPCR strategy with examination of only selected
common aneuploidies (similar to FISH) coupled with
trophectoderm biopsy of Day 5/6 blastocyst stage em-
bryos can still achieve a favorable reproductive outcome.
It is ethical since it is by theory better than the trial
protocol reported in the “Mastenbroek controversy” trial
[3], in which a similar number of aneuploidies was
assessed by FISH but the biopsy timing was set at Day 3
(when cleavage-stage embryos), a timing now being rec-
ognized to be inferior to Day 5/6 blastocyst stage regard-
ing the implantation potential [9]. After the feasibility is
confirmed in our setting, it is then justified to expand
the repertoire of aneuploidies to 9 chromosomes (13, 15,
16, 17, 18, 21, 22, X and Y. See Rubio et al., 2013a [5]),
or 11 chromosomes (7, 9, 11, 13, 14, 15, 18, 21, 22, X
and Y. These are the most commonly found trisomies at
abortus. See Wang et al., 2014 [21]) and eventually to 24




Pre-clinical validation for the PGS by qPCR was per-
formed on 54 surplus frozen embryos (Additional file 1:
Table S1). Fifty-three of these embryos were successfully
diagnosed and the successful diagnostic rate was 98.1 %
(53/54). Twenty-four embryos were found to carry aneu-
ploidy on tested chromosomes and the rate of aneu-
ploidy was thus 44.4 % (24/53). The only embryo failed
to provide a confirmed diagnosis showed poor qPCR sig-
nal, possibly due to a low amount of or degraded DNA
in the biopsied sample. FISH diagnosis for that embryo
was negative for numerical disorders involving chromo-
some 13, 18, 21, X, and Y. The remaining cells of this bi-
opsied embryo were sent for array CGH and the
diagnosis was trisomy 22.
Clinical verification
A total of 72 embryos at Day 5/6 blastocyst stage from
13 patients were biopsied and assessed, and all (100 %)
of them were successfully diagnosed (Table 1 and
Table 1 Clinical outcomes of PGS by qPCR with fresh embryo




Embryos diagnosed (%) 72 100.0 %
Embryos with diagnosis failure 0 0
Aneuploid embryos 28 38.9 %
Embryo transferred (ET) 28
Mean embryos transferred 2.15
Clinical pregnancies (% cycles) 8 61.5 %
Early miscarriages (<12 weeks) 1 12.5 %
Ongoing pregnancies (% cycles) 7 53.8 %
Embryonic sacs 11
Embryonic heart tone (FHT) 11
Sustained implantation rate (% ET) 11/28 39.3 %
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these embryos were aneuploid, which included 4 mono-
somy 13, 5 monosomy 21, 7 trisomy 13, 1 trisomy 18, 9
trisomy 21, 1 monosomy 13 + trisomy 18, and 1 mono-
somy 18 +monosomy 21. The remaining 44 (61.1 %)
embryos were euploidy, of which 28 were transferred
into the 13 patients in 13 cycles. The average number of
the embryos being transferred is 2.15, actually only 1–2
embryos were transferred in all women of the Group B
(non-AMA group, n = 10). The only 2 women who were
transferred for 4 embryos are both in the Group A
(AMA group, n = 3). The transfer procedure follows the
medical rule of Taiwan that the upper limit of the num-
ber of the embryos being transferred is 4. These trans-
fers achieved 8 pregnancies, and therefore the clinical
pregnancy rate was 61.5 % (8/13) per cycle. However,
one early abortion was noted and the ongoing pregnancy
rate up to the second trimester was 53.8 % (7/13) per
transfer cycle. There were no monozygotic twinning and
a total of 11 sacs were noted. Three women who were
transferred for 2 embryos in the Group B had singleton
pregnancies, and two women who were transferred for 2
embryos in the Group B and 2 women who were trans-
ferred for 4 embryos in the Group A had dizygotic twin
pregnancies (Additional file 1: Table S1). The sustained
implantation rate was thus 39.3 % (11/28) per trans-
ferred fresh embryo (Table 1). Totally, there are 2 of 3
women in Group A had ongoing pregnancies. Six
women in Group B had clinical pregnancies, and 5 of
them had sustained ongoing pregnancies. There are no
statistical significant differences noted between these
two groups regarding aneuploidy (Chi square test, p =
0.094), clinical pregnancy (Fisher's exact test, p = 1), and
ongoing pregnancy (Fisher's exact test, p = 1). ArrayCGH for the only abortion case revealed the karyotype
was 46,XY.
Discussion
The major difficulty of comprehensive chromosome
screening (CCS) by qPCR for PGS is to devise a primer
set to successfully amplify the molecular markers being
selected in a single experiment by optimizing the condi-
tions for melting temperatures and experimental time
intervals. In this study we successfully adopted a smart
design called LNA methodology [20, 22–24] for qPCR
PGS and verified the strategy by achieving a favorable
ongoing pregnancy rate of 53.8 %. We first validated the
genotyping platform we devised by achieving an almost
100 % successful diagnosis rate (98.1 %), and then veri-
fied the whole protocol of qPCR PGS followed by FET.
Since the sample size is small (n = 13 cycles), it is not
surprising that we failed to observe significant differ-
ence regarding the aneuploidy rates between the AMA
(n = 3) and the non-AMA group (n = 10) in our pa-
tients. Meanwhile, the aneuploidy rate in our series
(38.9 %) is apparently much lower than the rates ob-
served by 24-chromosome qPCR or array CGH (more
than 60 %), which is obviously due to the fact that we
only selected a limited set of common aneuploidies that
can ensue live births in humans [14, 15].
It has been a routine practice in our settings that PGS
by FISH at Day 3 cleavage-stage embryos since 2005 and
it is ethical for us to offer our patients who opted for
this alternative protocol a strategy which has an advan-
tage of an established less detrimental effect upon im-
plantation potential by changing the timing of biopsy
from Day 3 to Day 5/6 and the same repertoire of com-
mon aneuploidies being tested (but simply using qPCR
instead of FISH) to enable FET [9]. The reason only tri-
somy 13, 18, 21, and numerical disorders involving X
and Y were tested in our settings is because these are
the only aneuploidies that may result in live births in
humans. For people who opted for this strategy and
came to our clinics, their major concern is more focused
at aneuploidies instead of live birth rates. In addition, it
is well recognized that despite fewer embryos would be
available for transfer if being cultured in vitro onto the
blastocyst stage when compared with the cleavage-stage
embryos, the disadvantage may be offset by the fact that
the aneuploidy rate of the blastocysts is much lower
than of the cleavage-stage embryos. An observational
study had reported that karyotypic evolution did exist in
early human embryogenesis, in which some cleavage
stage embryos classified as aneuploidy by FISH eventu-
ally developed into euploid blastocysts if by SNP array
[25]. A recent randomized study even pointed out that
FISH-based PGS conferred advantages at women who
are in the AMA group, but not in those with repeated
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performed at the blastocyst stage [5].
A recent randomized trial (the BEST trial) had demon-
strated that qPCR PGS CCS followed by single embryo
transfer (SET) can enhance the feasibility of SET by
selecting a single euploid embryo with high reproductive
potential without compromising the delivery rates when
compared with transfer of two unselected embryos,
which instead resulted in more multiple pregnancies and
the associated complications such as preterm delivery,
low birth weight, and NICU (Neonatal Intensive Care
Unit) admission [26]. We admit our pilot verification
study had suffered from the fact that only common an-
euploidies of five chromosome pairs (13, 18, 21, X, and
Y) were screened and apparently it is the reason that the
implantation rate per embryo in our study (39.3 %) is
much lower than that in the BEST trial (69 %) [26].
However, our patients were all informed consented and
knew the disadvantage before joining the study, and the
limitations of the local setting were clearly disclosed to
the patients. The patients were free to choose another
PGS protocol by array CGH (Option 2, please refer to
Patients and methods section) instead.
Conclusions
The merit of our work is that this is the first effort from
research groups other than the original group who pro-
posed the qPCR CCS (Reproductive Medicine Associates
of New Jersey, Morristown, NJ, USA) trying to validate



















ahttp://genome.ucsc.edudeveloped in-house by ourselves. Despite our results did
not have matched controls such as those cycles receiving
IVF but without PGS, the ongoing pregnancy rate
is similar to a previous PGD series from our setting
(53.8 % versus 50 %, please refer to Chang et al., 2013
[27]), indicating this protocol is clinically feasible. Future
efforts will be made upon expanding the repertoire of
the PGS by qPCR CCS to all 24 chromosomes, as well
as carefully-designed randomized controlled trials to
compare this genotyping platform with others (including
no-screening, array CGH, and NGS).
Patients and methods
Design and selection of molecular markers for qPCR PGS
An in-house screening system by dual-color qPCR was
developed with specific primers for the targeted loci (sit-
uated at chromosome 13, 18, 21, X, and Y) and one in-
ternal control locus (situated at chromosome 1, the
reason we chose chromosome 1 as control is because it
is the least found trisomy in humans, see Wang et al.,
2014 [21]). A total of 16 targeted loci and one control
locus were selected. For the detailed information about
the targeted loci, please refer to Table 2. Specific primers
for amplification of each locus were designed by using
the software Oligo 6.71 (Molecular Biology Insights,
Colorado, USA), and all primer sets are flanked on each
side of the exon-intron boundary to avoid possible
mRNA interference. The applications of LNA-modified
probes are well-established for quantifying levels of
gene expression with an advantage of reducinganeuploidies
Gene UCSC genomic regiona





ZNF236 >chr18:74592149 + 74592311
CTDP1 >chr18:77513630 + 77513793
URB1 >chr21:33706443-33706522
TIAM1 >chr21:32582475 + 32582617
TRAPPC10 >chr21:43279112-43279286
PRDM15 >chr21:43279123-43279253
ZFY >chrY:2844794 + 2844938
KDM5D >chrY:21871564-21871720
ZFX >chrX:24226424 + 24226508
HUWE1 >chrX:53573627-53573781
EFNB1 >chrX:68060064 + 68060172
XPNPEP2 >chrX:128873173 + 128873264
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tection of chromosomal copy number alterations. Two
kinds of LNA-modified probes, labeled with FAM™ and
HEX™ (Integrated DNA Technologies, Iowa, USA) at
the 5’-end, were used for quantifying the genomic copy
numbers of targeted loci and control.Fig. 1 The diagram of the in-house qPCR PGS system. The flowchart of (a)
data analysisValidation of qPCR in detecting common aneuploidies
Each 5 cells separated from the cell lines of known com-
mon aneuploidies (including trisomy 21, trisomy 13,
trisomy 18, 47,XXY, and 45,X) were processed by cell
lysis of proteinase K, and the products were subjected
to a 50-μL reaction volume of multiplex nested-PCRdetection of common aneuploidies, and (b) signal normalization and
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Veriti thermal cycler (Life Technologies, California,
USA), and then the PCR products were purified using
Agencourt AMPure XP system (Beckman Coulter,
California, USA). Dual color hydrolysis probe assays
were performed in triplicate to normalize and simpify
calculation and to evaluate chromosomal copies, using
Lightcycler 480 probes Master (Roche, Mannheim,
Germany), a 20-μL reaction volume, a 96-well plate, and
a 7 Light Cycler 480 Real-Time PCR System, as recom-
mended by the supplier (Roche, Mannheim, Germany).
Each well contains a particular target, and a common
control reaction. A unique method of the standard delta
delta threshold cycle (ΔΔCp) method was used for rela-
tive quantification. In our experiments, the Cp variation
of all HEX™ reactions obtained for each well of the same
sample will be controlled and ranged in less than 0.2, in-
dicating the test sample was evenly distributed to each
well. Each chromosome-specific ΔCp was calculated
from the Cp of the FAM™ reactions targeting a specific
chromosome minus the control Cp of the HEX™ reac-
tions targeting the chromosome 1 within the same well.
The same process was applied to individually determine
the ΔCp for each targeted chromosome of the test sample,
including reference set of normal male cell lines [BCRC
number: 08C0011, 08C0012, 08C0013, 08C0021 and
08C0025]. Each chromosome- specific ΔCp was then nor-
malized to the average chromosome-specific ΔCp values
derived from the same evaluation of the reference set,
which had been confirmed by FISH method. The cali-
brated chromosome-specific ΔCp values were used to cal-
culate fold change by considering the ΔΔCp values as the
negative exponent of 2, as previously described [18, 23].
The methodology was designed to specifically identify
whole-chromosome but not segmental aneuploidy. The
flowchart and diagram of the in-house qPCR PGS system
were illustrated in Fig. 1. This qPCR was capable of accur-
ate aneuploidy screening in 4 h, which allowed rapid
evaluation of the trophectoderm biopsies and therefore
provided a feasible opportunity for subsequent FET.
Pre-clinical validation upon surplus frozen embryos
Fifty-four thawed frozen embryos at blastocyst stage
were biopsied and sent for qPCR and FISH analyses.
These embryos were retrieved from the surplus frozen
embryos of couples who already conceived and would
be discarded if not being investigated for research pur-
pose. In those embryos diagnosed with common
chromosome aneuploidies, array CGH was used to con-
firm the diagnoses.
Clinical verification for fresh embryos
In our setting we used to offer two PGS protocols. One
option (Option 1) is Day 3 biopsy followed by PGS withFISH and FET; the other option (Option 2) is Day 5/6
trophectoderm biopsy followed by PGS with array CGH
and frozen embryo transfer (because array CGH takes
time and FET was not feasible at the study period). Only
patients who had history of failed IVF (without PGS) for
at least once and who opted for Option 1 were given the
chance of joining this study as an alternative. All pa-
tients chose to join this study were informed consented
and their autonomy was fully respected. They could
choose to withdraw from the study at any time during
the study period and were fully aware of the alternatives,
including sticking to Option 1 or instead chose Option 2
without joining the study. During July to October of
2014, 13 infertile couples were enrolled. Among these 13
patients, 3 of them had AMA (37, 43, 45 years old re-
spectively). The mean age of the total 13 patients was
34.1 years. No confounding factors that may affect im-
plantation such as immune aberrations (antiphospholi-
pid antibody syndrome in the mother), balanced
translocation carriers (in both couples), and thrombo-
philias (protein C/S/antithrombin III deficiency) existed
in these couples when they were enrolled. Clinical preg-
nancy was defined as positive urine HCG. Ongoing preg-
nancy rate (per cycle) was defined as those pregnancies
proceeding into second trimester (and for each embryo
being transferred, sustained implantation rate was used).
13 couples were classified as those whose age is older or
equal to 35 years (Group A), and those whose age is less
than 35 years (Group B). Chi square test or Fisher’s
exact test was used to compare the reproductive out-
comes between the groups regarding the rate of aneu-
ploidy, clinical pregnancy, and ongoing pregnancy.
Notably according to the regulations of Taiwan govern-
ment, the patients would not know the results of the
fetal sex. Even in aneuploidies involving sex chromo-
somes (specifically 47,XXY and 45,X), the results would
not be disclosed to patients and only “aneuploidy”
would be told to the patients and the aneuploid em-
bryos would not be selected for transfer. In those em-
bryos diagnosed to have chromosomal aneuploidies by
qPCR, array CGH was used to confirm the diagnoses.Additional file
Additional file 1: Table S1. Summary of the pre-clinical validation (for
54 surplus frozen embryos) and clinical verification (for 13 patients with
54 embryos) of PGS by qPCR.Abbreviations
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nucleic acid; NGS: Next generation sequencing; PGS: Preimplantation genetic
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SET: Single embryo transfer; SNP: Single nucleotide polymorphism.
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